| William J. Sibold |
William J. Sibold is currently the Chief Executive Officer at True North Therapeutics, Inc. He is also the President, Chief Executive Officer & Director at Madrigal Pharmaceuticals, Inc. Additionally, he holds the position of President & Director at Bioverativ Therapeutics, Inc. and Director at Biotechnology Innovation Organization. Previously, he served as the President at Bioverativ, Inc. and held executive roles at Lycera Corp., Genzyme Corp., Amgen, Inc., Biogen, Inc., Avanir Pharmaceuticals, Inc., Sanofi, and Eli Lilly Canada, Inc. Mr. Sibold completed his undergraduate degree at Yale University and earned an MBA from Harvard Business School. |
| Clint Wallace |
Clint Wallace is currently the Chief Human Resources Officer at Madrigal Pharmaceuticals, Inc. He previously worked as the Senior Vice President-Human Resources at Kenvue, Inc. Mr. Wallace has an undergraduate degree from Central Connecticut State University and an MBA from Rensselaer Polytechnic Institute. |
| Edward Chiang |
Edward Chiang was the founder of Madrigal Pharmaceuticals, Inc. where he held the title of Head-Clinical Operations in 2011 and SVP-Clinical & Technical Operations from 2011. He also worked as an Associate Director-Clinical Operations at VIA Pharmaceuticals, Inc. from 2006 to 2011, a Project Manager at Beacon Bioscience, Inc., and a Manager-Clinical Trials at Bracco Diagnostics, Inc. from 1997 to 2004. Mr. Chiang received his undergraduate and graduate degrees from the University of Michigan. |
| Tina Ventura |
Tina Ventura is currently the Director at Lake Forest Open Lands Association, a Trustee at Lake Forest Country Day School, and the Chief Investor Relations Officer at Madrigal Pharmaceuticals, Inc. She previously worked as the Chief Investor Relations Officer & Senior VP at Horizon Therapeutics Plc. Ventura received an undergraduate degree from Northwestern University and an MBA from Loyola University of Chicago. |
| Mark G. Barrett |
Mark G. Barrett is the founder of Lassen Therapeutics LLC, Lassen Therapeutics 1, Inc. He is currently the Chief Business Officer at Madrigal Pharmaceuticals, Inc. He completed his undergraduate degree at Duke University and his MBA at Berkeley University of California. |
| Robert Waltermire |
Robert Waltermire is currently the Chief Pharmaceutical Development Officer at Madrigal Pharmaceuticals, Inc. Prior to this, he worked at Venatorx Pharmaceuticals, Inc. for 32 years as the Senior Vice President-CMC. He received his undergraduate degree from Franklin & Marshall College in 1984 and his doctorate from the University of Maryland in 1988. |
| Stephen Dodge |
Stephen Dodge currently works at Madrigal Pharmaceuticals, Inc., as Senior Vice President-Global Medical Affairs. |
| Carole Huntsman |
Carole Huntsman is currently the Chief Commercial Officer at Madrigal Pharmaceuticals, Inc. Prior to this, she worked as the Senior VP & Head-Specialty Care North America at Sanofi. She completed her undergraduate degree at Boston College and earned an MBA from The Carroll School. |
| Ronald Filippo |
Ronald Filippo is currently the Chief Information Officer at Madrigal Pharmaceuticals, Inc. Prior to his current position, he served as the Senior Vice President-Digital at Moderna, Inc. from 2021 to 2023. He also held the position of Head-Data & AI Transformation at Teva Pharmaceuticals, Inc. Mr. Filippo completed his undergraduate degree at Thomas Jefferson University. |
| Rebecca A. Taub |
Rebecca A. Taub was the founder of Madrigal Pharmaceuticals, Inc. (founded in 2011) where she held the title of Chief Executive Officer in 2011. She is also the founder of Madrigal Pharmaceuticals, Inc. (founded in 2016) where she currently holds the title of Director, President-Research & Development. Dr. Taub's current job is as an Independent Director at BriaCell Therapeutics Corp. (since 2018). Her former jobs include Executive Director-CNS & Obesity Research at Bristol Myers Squibb Co. (2000-2003) and DuPont Pharmaceuticals Co. (2000-2003), Vice President-Research at Roche Pharmaceuticals, Inc., Professor at the University of Pennsylvania (1987-2002), Vice President-Research & Metabolic Diseases at Hoffmann-La Roche, Inc. (2004-2007), Associate Investigator at Howard Hughes Medical Institute, Inc., Senior Vice President-Research & Development at VIA Pharmaceuticals, Inc. (2008-2011), Assistant Professor at Harvard Medical School, and Professor at Perelman School of Medicine (1997-2001). Dr. Taub's education includes a doctorate from Yale School of Medicine and an undergraduate degree from Yale College. |
| Mardi C. Dier |
Mardi C. Dier is currently serving as an Independent Director at Oric Pharmaceuticals, Inc., Prelude Therapeutics, Inc., and Synthekine, Inc. They are also an advisor at Healthcare Royalty Management LLC. Additionally, Ms. Dier holds the position of Chief Financial Officer & Senior Vice President at Madrigal Pharmaceuticals, Inc. In their former roles, Ms. Dier served as a Director at Futures Strategic Trust and Prudential Securities. They were an Independent Director at Adamas Pharmaceuticals LLC from 2017 to 2021 and held the position of Director-Investment Banking at Prudential Equity Group LLC from 1994 to 2001. Ms. Dier also served as a Director at Jewish Vocational Service, Inc. and Vice President-Investor Relations at Chiron Corp. from 2003 to 2006. From 2006 to 2020, they held the positions of CFO, Chief Business Officer & Executive VP at Portola Pharmaceuticals LLC. They were also the Chief Financial Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc. from 2020 to 2022. Ms. Dier worked as a Senior Accountant at KPMG LLP and KPMG Peat Marwick LLP from 1986 to 1990. They briefly served as the Chief Business Officer at ACELYRIN, Inc. in 2023. Ms. Dier completed their undergraduate studies at Stanford University in 1986 and obtained an MBA from UCLA Anderson School of Management in 1992. |
| Paul A. Friedman |
Paul A. Friedman's current jobs include being the Chairman at Prelude Therapeutics, Inc., a Director at Madrigal Pharmaceuticals, Inc., and a Member of the American Society for Clinical Investigation, the American Society for Biochemistry & Molecular Biology, Inc., and the American Society for Pharmacology & Experimental Therapeutic. Formerly, Dr. Friedman held positions such as Director at Bausch & Lomb, Inc., Independent Director at Incyte Corp., Alexion Pharmaceuticals, Inc., and Auxilium Pharmaceuticals LLC, and President-Research & Development at DuPont Merck Pharmaceutical Co. He also served as a Senior Vice President at Merck Research Laboratories Massachusetts LLC and President at DuPont Pharmaceuticals Research Laboratories. Additionally, he was an Associate Professor-Medicine & Pharmacology at Harvard Medical School. Dr. Friedman obtained his undergraduate degree from Princeton University and his doctorate from Harvard Medical School. |
| Julian Charles Baker |
Julian Charles Baker is the founder and the Managing Partner of Baker Bros. Advisors LP, which was founded in 2000. He is currently the Independent Chairman at Madrigal Pharmaceuticals, Inc. since 2023, Lead Independent Director at Incyte Corp. since 2001, Independent Director at ACADIA Pharmaceuticals, Inc. since 2015, Independent Director at Prelude Therapeutics, Inc. since 2021, Director at EveryONE Medicines, Inc., Director at Alumis, Inc., Managing Member at Baker Bros. Advisors GP LLC, and Partner at FBB Associates. Mr. Baker has held former positions as Director at Neurogen Corp. from 1999 to 2009, Independent Director at Idera Pharmaceuticals, Inc. from 2014 to 2018, Director at Trimeris, Inc. from 2004 to 2011, Lead Independent Director at Genomic Health, Inc. from 2001 to 2019, Director at Innoviva, Inc. from 1999 to 2007, Director at Presidio Pharmaceuticals, Inc., Member at Credit Suisse First Boston Corp. from 1988 to 1993, Principal at CSFB Private Equity Partners LLC, Advisory Board Member at Elm Street Advisors LLC, and Portfolio Manager at Tisch Financial Management from 1994 to 1999. Mr. Baker obtained his undergraduate degree from Harvard University. |
| Kenneth M. Bate |
Kenneth M. Bate is the founder of JSB-Partners LP, which was founded in 1999. He is currently the Chairman of Genocea Biosciences, Inc. since 2018, Chairman of Astria Therapeutics, Inc. since 2019, and Independent Director of Madrigal Pharmaceuticals, Inc. since 2016. Previously, he served as President, Chief Executive Officer & Director of NitroMed, Inc. from 2007 to 2009, President, Chief Executive Officer & Director of Archemix Corp. from 2011 to 2012, Chief Executive Officer of MPM BioImpact, Inc. from 1997 to 1999, Lead Independent Director of Cubist Pharmaceuticals LLC from 2015 to 2016, Independent Non-Executive Director of BioMarin Pharmaceutical, Inc. from 2014 to 2017, Director of Coley Pharmaceutical Group, Inc. from 2005 to 2008, Independent Director of Vanda Pharmaceuticals, Inc. from 2015 to 2018, Director of TransMedics, Inc. from 2012 to 2017, and Lead Independent Director of AVEO Pharmaceuticals, Inc. since 2007. He also served as an Independent Director of Epizyme, Inc. from 2014 to 2022. Mr. Bate's education includes an undergraduate degree from Williams College and an MBA from The Wharton School of the University of Pennsylvania. |
| Richard S. Levy |
Richard S. Levy is currently serving as a Non-Executive Director at Gliknik, Inc., an Independent Director at Kiniksa Pharmaceuticals Ltd., Madrigal Pharmaceuticals, Inc., Kodiak Sciences, Inc., and Protara Therapeutics, Inc. He has previously worked as an Independent Director at Aquinox Pharmaceuticals, Inc. and Constellation Pharmaceuticals, Inc. He has also served as a Vice President at Celgene Corp., Chief Drug Development & Medical Officer, EVP at Incyte Corp., and Vice President at DuPont Pharmaceuticals Co. He started his career as an Assistant Professor at David Geffen School of Medicine. Dr. Levy has an undergraduate degree from Brown University and doctorate degrees from the University of Pennsylvania and Perelman School of Medicine. |
| James M. Daly |
James M. Daly is currently serving as an Independent Director at ACADIA Pharmaceuticals, Inc., argenx SE, and Madrigal Pharmaceuticals, Inc. He previously held positions as an Independent Director at Halozyme Therapeutics, Inc., Chimerix, Inc., and Bellicum Pharmaceuticals, Inc. He also served as the SVP-Global Marketing & Commercial Development at Amgen, Inc. from 2002 to 2011 and as the Chief Commercial Officer & Executive VP at Incyte Corp. from 2012 to 2015. Additionally, he has held positions at Coherus BioSciences, Inc., Amgen Ventures LLC, and Francis Cauffman, Inc. Mr. Daly obtained his undergraduate degree in 1983 and an MBA in 1985 from the State University of New York at Buffalo. |
